Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Multiple myeloma remains an incurable disease. One of the major problems is that myeloma cells develop drug resistance on interaction with bone marrow stromal cells. In this study, we examined the effects of macrophages (Mvarphis), a type of stromal cells, on myeloma cell survival and response to chemotherapy. We showed that Mvarphi, in particular tumor-associated Mvarphi, is a protector of myeloma cells. The protective effect was dependent on direct contact between Mvarphis and myeloma cells. Mvarphis protected both myeloma cell lines and primary myeloma cells from spontaneous and chemotherapy drug-induced apoptosis by attenuating the activation and cleavage of caspase-dependent apoptotic signaling. These findings are clinically relevant because we found that CD68+ Mvarphis heavily infiltrate the bone marrow of patients with myeloma but not the bone marrow of control patients. Thus, our results indicate that Mvarphis may contribute to myeloma cell survival and resistance to chemotherapeutic treatment in vivo.

[1]  E. Shpall,et al.  Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. , 2006, Blood.

[2]  W. Dalton Drug resistance and drug development in multiple myeloma. , 2002, Seminars in oncology.

[3]  Michael L. Wang,et al.  Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. , 2006, Cancer cell.

[4]  R. Kyle,et al.  Multiple myeloma. , 2008, Blood.

[5]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[6]  B. Barlogie,et al.  Cancer and the Microenvironment , 2004, Cancer Research.

[7]  M. Jourdan,et al.  Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. , 1990, European cytokine network.

[8]  Michael L. Wang,et al.  Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. , 2007, Cancer cell.

[9]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[10]  R. Crystal,et al.  Antigen-pulsed dendritic cells expressing macrophage-derived chemokine elicit Th2 responses and promote specific humoral immunity. , 2001, The Journal of clinical investigation.

[11]  J. Epstein,et al.  Consequences of interactions between the bone marrow stroma and myeloma. , 2003, The hematology journal : the official journal of the European Haematology Association.